ANDA approvals
This article was originally published in The Tan Sheet
Executive Summary
Alpharma receives FDA clearance for private label permethrin lotion 1% (ANDA 75-014) on March 28. The product is the first approved generic version of Warner-Lambert's Nix pediculicide, the company says. Alpharma plans to launch the private label product April 1 in 60 mL bottles in single-, double- and triple-packs. Pfizer's Rid, which contains pyrethrum extract, was extended with a mousse delivery form approved March 7 under an "NDA Deviation" (1"The Tan Sheet" March 13, p. 4). Cheminor also receive ANDA approval March 28 for a generic version of a Warner product. The company's ranitidine 75 mg tablets (ANDA 75-294) will compete with the W-L reference drug, Zantac 75; the H2 antagonist lost its marketing exclusivity last June
You may also be interested in...
Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"
FDA approved an "NDA Deviation" (21-043) for Pfizer's Maximum Strength Rid Mousse aerosolized foam lice treatment March 7. It is one of the first "NDA Deviations" to get the go-ahead from the agency; such an application is for a product that is comparable to products in a monograph but deviates in a significant way.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands